Cargando…
Palmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats
This study aimed to exploit the potential therapeutic value of palmatine in treatment of cardiac hypertrophy and the underlying molecular mechanism. Rat hypertrophy model was established by intraperitoneal isoproterenol (ISO) injection. The hypertrophy was evaluated with cardiac hypertrophic paramet...
Autores principales: | Yuan, Yonggang, Peng, Wanzhong, Liu, Yongxing, Xu, Zesheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806808/ https://www.ncbi.nlm.nih.gov/pubmed/29164959 http://dx.doi.org/10.1177/0394632017742225 |
Ejemplares similares
-
Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway
por: Zhao, Tingwei, et al.
Publicado: (2021) -
Puerarin attenuates isoproterenol-induced myocardial hypertrophy via inhibition of the Wnt/β-catenin signaling pathway
por: Wang, Xiaoying, et al.
Publicado: (2022) -
Musa balbisiana Fruit Rich in Polyphenols Attenuates Isoproterenol-Induced Cardiac Hypertrophy in Rats via Inhibition of Inflammation and Oxidative Stress
por: Kumari, Sima, et al.
Publicado: (2020) -
Circulating miR‐130 and its target PPAR‐γ may be potential biomarkers in patients of coronary artery disease with type 2 diabetes mellitus
por: Yuan, Yonggang, et al.
Publicado: (2019) -
STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways
por: Liu, Fei, et al.
Publicado: (2020)